Postoperative Hypofractionated Volumetric Modulated Arc Therapy with a Simultaneous Integrated Boost for Soft Tissue Sarcomas
Abstract
Soft tissue sarcomas (STS) are rare neoplasms whose standard treatment combines surgery and radiotherapy. Conventional postoperative radiotherapy regimens involve prolonged treatment courses, which has prompted the exploration of hypofractionated alternatives. The development of advanced techniques, such as intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT), together with the use of a simultaneous integrated boost (SIB), allows biologically equivalent doses to be delivered over a shorter period, optimizing dose distribution and reducing irradiation of healthy tissues. We present a retrospective series of 51 patients with STS treated with postoperative hypofractionated radiotherapy delivered in 15 fractions. Acute and late toxicity and oncologic outcomes were evaluated. The results showed satisfactory local control and survival, a low incidence of acute toxicity, and a moderate rate of late fibrosis. These findings suggest that hypofractionation using IMRT/VMAT is a viable therapeutic alternative in selected settings.Downloads
References
Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, et al. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol 2022;17(2):200-13. https://doi.org/10.1016/j.jtho.2021.10.010
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7-30. https://doi.org/10.3322/caac.21590
Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv51-
https://doi.org/10.1093/annonc/mdy096
Choi JH, Ro JY. The 2020 WHO Classification of tumors of soft tissue: Selected changes and new entities. Adv Anat Pathol 2021;28(1):44-58. https://doi.org/10.1097/PAP.0000000000000284
World Health Organization. Soft tissue and bone tumours. Lyon: International Agency for Research on Cancer
(IARC) - World Health Organization; 2020, p. 2-6.
Cammelli S, Cortesi A, Buwenge M, Zamagni A, Ferioli M, Ghigi G, et al. The role of radiotherapy in adult soft tissues sarcoma of the extremities. Eur J Orthop Surg Traumatol 2021;31(8):1583-96. https://doi.org/10.1007/s00590-021-02990-6
Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol 2014;21(8):2484-9. https://doi.org/10.1245/s10434-014-3732-4
Kachare SD, Brinkley J, Vohra NA, Zervos EE, Wong JH, Fitzgerald TL. Radiotherapy associated with improved survival for high-grade sarcoma of the extremity. J Surg Oncol 2015;112(4):338-43. https://doi.org/10.1002/jso.23989
O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359(9325):2235-41. https://doi.org/10.1016/S0140-6736(02)09292-9
Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16(1):197-203. https://doi.org/10.1200/JCO.1998.16.1.197
Holt GE, Griffin AM, Pintilie M, Wunder JS, Catton C, O’Sullivan B, et al. Fractures following radiotherapy and limb-salvage surgery for lower extremity soft-tissue sarcomas. A comparison of high-dose and low-dose radiotherapy. J Bone Joint Surg Am 2005;87(2):315-9. https://doi.org/10.2106/JBJS.C.01714
El-Bared N, Wong P, Wang D. Soft tissue sarcoma and radiation therapy advances, impact on toxicity. Curr Treat Options Oncol 2015;16(5):19. https://doi.org/10.1007/s11864-015-0335-7
Alektiar KM, Hong L, Brennan MF, Della-Biancia C, Singer S. Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results. Int J Radiat Oncol Biol Phys 2007;68(2):458-64. https://doi.org/10.1016/j.ijrobp.2006.12.054
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67(2):93-9. https://doi.org/10.3322/caac.21388
U. S. Department of Health and Human Services – National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Disponible en: https://dctd.cancer.gov/research/ctep-trials/trial-development
Haas RLM, Delaney TF, O’Sullivan B, Keus RB, Le Pechoux C, Olmi P, et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? Int J Radiat Oncol Biol Phys 2012;84(3):572-80. https://doi.org/10.1016/j.ijrobp.2012.01.062
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53(282):457-81. https://doi.org/10.1080/01621459.1958.10501452
Kishore J, Goel M, Khanna P. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 2010;1(4):274. https://doi.org/10.4103/0974-7788.76794
Wang J, Wang S, Song Y, Liu X, Jin J, Wang W, et al. Postoperative intensity-modulated radiation therapy provides favorable local control and low toxicities in patients with soft tissue sarcomas in the extremities and trunk wall. Onco Targets Ther 2015;8:2843-7. https://doi.org/10.2147/OTT.S88227
Bourdais R, Achkar S, Honoré C, Faron M, Cavalcanti A, Auzac G, et al. Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume? Clin Transl Radiat Oncol 2021;29:79-84. https://doi.org/10.1016/j.ctro.2021.05.007
Di Brina L, Fogliata A, Navarria P, D’Agostino G, Franzese C, Franceschini D, et al. Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. Br J Radiol 2019;92(1102):20190252. https://doi.org/10.1259/bjr.20190252
Seddon B, Grange FL, Simões R, Stacey C, Shelly S, Forsyth S, et al. The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys 2024;120(4):978-89. https://doi.org/10.1016/j.ijrobp.2024.05.024
Mills M, Miller J, Liveringhouse C, Bryant JM, Kawahara Y, Feygelman V, et al. Novel postoperative hypofractionated accelerated radiation dose-painting approach for soft tissue sarcoma. Adv Radiat Oncol 2024;9(3):101391. https://doi.org/10.1016/j.adro.2023.101391
Manuscript acceptance by the Journal implies the simultaneous non-submission to any other journal or publishing house. The RAAOT is under the Licencia Creative Commnos Atribución-NoComercial-Compartir Obras Derivadas Igual 4.0 Internacional (CC-BY-NC.SA 4.0) (http://creativecommons.org/licences/by-nc-sa/4.0/deed.es). Articles can be shared, copied, distributed, modified, altered, transformed into a derivative work, executed and publicly communicated, provided a) the authors and the original publication (Journal, Publisher and URL) are mentioned, b) they are not used for commercial purposes, c) the same terms of the license are maintained.
In the event that the manuscript is approved for its next publication, the authors retain the copyright and will assign to the journal the rights of publication, edition, reproduction, distribution, exhibition and communication at a national and international level in the different databases. data, repositories and portals.
It is hereby stated that the mentioned manuscript has not been published and that it is not being printed in any other national or foreign journal.
The authors hereby accept the necessary modifications, suggested by the reviewers, in order to adapt the manuscript to the style and publication rules of this Journal.
